NEW YORK (GenomeWeb) – SEngine Precision Medicine said today that its Seattle-based laboratory has received CLIA certification.

The company's primary test offering, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

SEngine said that its CLIA Laboratory now simultaneously screens up to 120 individual drugs and selected drug combinations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.